<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511979</url>
  </required_header>
  <id_info>
    <org_study_id>PDC-INS-0002</org_study_id>
    <nct_id>NCT00511979</nct_id>
  </id_info>
  <brief_title>Comparison of the Effect on the Glucose Infusion Rates Between Inhaled Technosphere Insulin and a Subcutaneous Injection of Regular Human Insulin</brief_title>
  <official_title>Effect of Different Doses of Inhaled Technosphere Insulin on Glucose Infusion Rates During Euglycemic Clamps in Comparison to a Subcutaneous Injection of Regular Human Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mannkind Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mannkind Corporation</source>
  <brief_summary>
    <textblock>
      A prospective, single center, open randomized, six way crossover study comparing the dose
      response effect of four different doses of Technosphere Insulin after pulmonary function
      delivery in comparison to s.c. injection of two different doses of regular human insulin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 1999</start_date>
  <completion_date type="Actual">June 2000</completion_date>
  <primary_completion_date type="Actual">February 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-corrected area-under-the serum insulin concentration vs. time curve for inhaled TI and subcutaneous RHI at timepoints -120, -90, -60, 0, 1, 3, 7, 12, 20, 30, 45, 60 and 90 minutes, and 2, 3, 4, 5 and 6 hours relative to treatment</measure>
    <time_frame>crossover every 3-28 days for up to 20 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the glucose infusion rate for inhaled TI and subcutaneous RHI at timepoints -120, -90, -60, 0, 1, 3, 7, 12, 20, 30, 45, 60 and 90 minutes, and 2, 3, 4, 5 and 6 hours relative to treatment</measure>
    <time_frame>crossover every 3-28 days for up to 20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety variables included adverse events (AEs), clinical laboratory tests, HbA1c, pulmonary function tests, vital signs, physical examinations, and diabetes-specific signs (ie, hypoglycemia)</measure>
    <time_frame>crossover every 3-28 days for up to 20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Technosphere insulin inhalation system, 25 units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Technosphere insulin inhalation system, 50 units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Technosphere insulin inhalation system, 100 units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous regular human insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technosphere Insulin</intervention_name>
    <arm_group_label>Technosphere insulin inhalation system, 25 units</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technosphere insulin</intervention_name>
    <arm_group_label>Technosphere insulin inhalation system, 50 units</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technosphere insulin</intervention_name>
    <arm_group_label>Technosphere insulin inhalation system, 100 units</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular human insulin</intervention_name>
    <arm_group_label>Subcutaneous regular human insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be in good health, as judge by brief history and physical examination.

          -  Sex: both, male and female.

          -  Age: 18-40 years.

          -  Body mass index: 18-27 kg/m2.

          -  Capability to reach peak inspiratory flow of &gt;41/sec measured by a computer assisted
             spirometry.

          -  FEV1 equal to or greater than 80% of predicted normal.

        Exclusion Criteria:

          -  Diabetes Mellitus type 1 or type 2.

          -  Human insulin antibodies.

          -  Anamnestic history of hypersensitivity to the study medication or to drugs with
             similar chemical structures.

          -  Having a history of severe or multiple allergies.

          -  Treatment with any other investigational drug in the last three months before study
             entry.

          -  Progressive fatal disease.

          -  History of significant cardiovascular, respiratory, gastrointestinal, hepatic, renal,
             neurological, psychiatric and /or hematological disease.

          -  Having ongoing respiratory tract infection.

          -  Smoker defined as subjects with evidence or history of tobacco or nicotine use in the
             last year prior to entry in the study.

          -  Blood donation within the last 30 days.

          -  A woman who is lactating.

          -  Pregnant women or women intending to become pregnant during the study.

          -  A sexually active woman of childbearing age not actively practicing birth control or
             using medically accepted device or therapy.

          -  A lack of compliance or other reasons, which prevent to the opinion of the
             investigator the participation of the subject in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2007</study_first_submitted>
  <study_first_submitted_qc>August 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2007</study_first_posted>
  <last_update_submitted>June 25, 2012</last_update_submitted>
  <last_update_submitted_qc>June 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Patients</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

